Skip to content

Role of the Environment in Pediatric Obesity

Role of the Environment in Pediatric Obesity

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07545174
Acronym
REOP
Enrollment
80
Registered
2026-04-22
Start date
2026-06-01
Completion date
2029-06-01
Last updated
2026-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity (Disorder)

Keywords

Obesity, PFAS, Environment

Brief summary

Childhood obesity is a particular concern in developed countries such as the United States, the United Kingdom, Canada, and certain European countries. According to the World Health Organization (WHO), approximately 6% of children under the age of 5 worldwide were obese in 2016, a figure that continues to rise. The pathophysiology of pediatric obesity can be explained by several interconnected biological and behavioral mechanisms. In particular, it involves dysfunctions in the hormones that regulate appetite and satiety, as well as dysfunctions in lipid metabolism. Per- and polyfluoroalkyl substances (PFAS) are a large family of synthetic chemical compounds. The main PFAS are perfluorooctanoic acid (PFOA), perfluorooctanesulfonic acid (PFOS), perfluorononanoic acid (PFNA), and perfluorohexanesulfonic acid (PFHxS). PFAS are present in many everyday consumer products. Bisphenol A (BPA) is a chemical compound used primarily in the manufacture of plastics and resins. It is commonly found in polycarbonate plastics, used to make food containers and water bottles, as well as in epoxy resins, which are used to coat the inside of food cans and water pipes. Non-persistent pesticides, such as organophosphates and polychlorinated biphenyls, are chemicals used primarily in agriculture to control insects and other pests. There are arguments suggesting that PFAS, bisphenol A, and non-persistent pesticides may play a role in the onset of pediatric obesity, particularly by acting.

Interventions

OTHERBlood test

Inclusion visit: during the routine blood test, one additional tube of blood will be collected for the study.

OTHERUrine sample

Inclusion visit: a urine sample will be collected for the study.

Inclusion visit: a hair sample will be taken from the patient.

Sponsors

University Hospital, Tours
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
6 Years to 15 Years
Healthy volunteers
Yes

Inclusion criteria

Patient with Obesity disorder : * Children with obesity (according to the BMI curves of the International Obesity Task Force/IOTF) * Follow-up within the obesity network of the Centre Val de Loire region (ObeCentre) Control group: * Children who are not obese (according to the BMI curves of the International Obesity Task Force/IOTF) All: * Children aged 6 to 15 at the time of inclusion (inclusive) * Whose two parents, or legal guardian, have signed an informed consent form * Patients affiliated with or covered by a social security system

Exclusion criteria

* Disorder preventing understanding of trial information or informed consent.

Design outcomes

Primary

MeasureTime frameDescription
PFOA concentrationAt the enrollment visitDifference in plasma PFOA concentration measured in ng/mL between obese and non-obese children (control group). PFOA will be measured in plasma using liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) at the Laberca laboratory.

Secondary

MeasureTime frameDescription
PFOS concentrationAt the enrollment visitDifference in plasma concentration of perfluorooctane sulfate (PFOS) measured in ng/mL between obese children and non-obese children.
PFNA concentrationAt the enrollment visitDifference in plasma concentration of perfluorononanoic acid (PFNA) measured in ng/mL between obese children and non-obese children
PFHxS concentrationAt the enrollment visitDifference in plasma concentration of perfluorohexanesulfonic acid (PFHxS) measured in ng/mL between obese children and non-obese children.
BPA concentrationAt the enrollment visitDifferences in urinary BPA concentrations measured in ng/mL between obese and non-obese children
Non-persistent pesticides concentrationAt the enrollment visitDifferences in urinary concentrations of non-persistent pesticides (organophosphates and polychlorinated biphenyls) in ng/mL between obese and non-obese children
Number of DNA breaksAt the enrollment visitDifferences in the number of DNA breaks in hair follicles between obese and non-obese children

Countries

France

Contacts

CONTACTJulien LEJEUNE
j.leujeune@chu-tours.fr+332 47 47 72 34
CONTACTCoralie TAILLEBUIS
c.taillebuis@chu-tours.fr+332 47 47 39 09

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 23, 2026